AR and prostate cancer: Treatment with the DNA demethylating agent 5-aza-2’-deoxycytidine (5-aza) reactivated AR expression, prevented the development of poorly differentiated prostate cancer and lymph node metastases, and significantly extended survival vs. control-treated mice (75).